Medicinal Chemistry bioRxiv
An ester prodrug finally lets SUGCT inhibitors work in cells
- Earlier crystal-structure-guided SUGCT inhibitors worked in vitro but not in cells, a gap for a target proposed for glutaric aciduria type I.
- The team ran a further biochemical screen and built a better cell-based readout.
- Masking valsartan as its ethyl ester prodrug improved cell entry and inhibited SUGCT in GA-1 cells; meclofenamic acid emerged as another cell-active inhibitor.
The open question is whether the ester is actually cleaved to the free acid inside cells. If not, intact ester versus released valsartan is ambiguous, and valsartan's AT1 pharmacology could muddy a GA-1 readout. Meclofenamic acid, an NSAID with known COX activity, looks like a tool at best. An inactive matched analog and a SUGCT knockout as controls, then a real SAR campaign, would be the way forward.
Paper: bioRxiv ↗ Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase